ABBV
AbbVie Inc.
Healthcare · Drug Manufacturers - General
Last price
US$ 250,94
▼ 2,51% on 31/07/2026
Fundamentals
Indicators
P/L
105,85
Relação entre o preço da ação e o lucro por ação (LPA) informado pela fonte de dados.
P/VP
-135,55
Compara o preço de mercado de uma ação ou cota com o valor contábil/patrimonial por ação ou cota (VPA).
Dividend Yield
2,69%
Percentual pago em proventos nos 365 dias anteriores ao cálculo em relação ao preço usado na coleta.
ROE
-129,24%
Relação entre o lucro atribuível aos controladores e o patrimônio líquido atribuível aos controladores.
Net Margin
6,91%
De cada R$ 1,00 de receita, quanto sobra como lucro depois de todos os custos, despesas e impostos.
Net Debt / EBITDA
—
Relação entre a dívida líquida e o EBITDA de uma empresa.
EPS
US$ 2,37
Valor de lucro por ação informado pela fonte de dados da empresa.
BVPS
-US$ 1,85
Quanto do patrimônio contábil da empresa (ou do fundo) corresponde a cada ação ou cota.
Reference: 31/12/2025 · All indicators: Financial Modeling Prep (FMP)
Income history
Recent dividends
| Type | Ex-date | Payment date | Value/share |
|---|---|---|---|
| dividendo | — | 14/08/2026 | US$ 1,73 |
| dividendo | — | 15/05/2026 | US$ 1,73 |
| dividendo | — | 17/02/2026 | US$ 1,73 |
| dividendo | — | 14/11/2025 | US$ 1,64 |
| dividendo | — | 15/08/2025 | US$ 1,64 |
| dividendo | — | 15/05/2025 | US$ 1,64 |
| dividendo | — | 14/02/2025 | US$ 1,64 |
| dividendo | — | 15/11/2024 | US$ 1,55 |
| dividendo | — | 15/08/2024 | US$ 1,55 |
| dividendo | — | 15/05/2024 | US$ 1,55 |
Context
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.